Autopsy report · NCT00083759
Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate
Cause of deathFunding or business
“The biological effect seen with natalizumab was not sufficient to warrant further development in RA.”
Life of this trial
- 299 participants enrolled.
- Results were posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Biogen
- Sponsor type
- Industry
- Conditions
- Rheumatoid Arthritis
- Interventions
- natalizumab; placebo
- Participants
- 299
- Sites
- 12
- Countries
- Canada, United States
Trials that died the same way
- Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
“The clinical development of intravenously administered ofatumumab in RA will no longer be pursued, so this study was prematurely terminated by the Sponsor.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.